These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 30228778)

  • 1. Drug resistance and new therapies in colorectal cancer.
    Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
    World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of adaptive immune effector therapies in solid tumors.
    Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
    Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
    Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune resilience in response to cancer therapy.
    Gicobi JK; Barham W; Dong H
    Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
    Grosser R; Cherkassky L; Chintala N; Adusumilli PS
    Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
    Bair SM; Mato A; Svoboda J
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
    Moehler M; Göpfert K; Lenz HJ
    Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targeting of the Colorectal Tumor Stroma.
    Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
    Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
    Cheung PF; Lutz M; Siveke JT
    Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
    Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
    World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
    Flaig TW
    J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
    Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
    Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
    Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
    Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of immune evasion in bladder cancer.
    Crispen PL; Kusmartsev S
    Cancer Immunol Immunother; 2020 Jan; 69(1):3-14. PubMed ID: 31811337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
    Tintelnot J; Stein A
    World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.